BioCentury
ARTICLE | Clinical News

Rexahn preclinical data

November 22, 2010 8:00 AM UTC

In vitro, a fluoro quinoxalinyl-piperazine derivative inhibited the growth of various cancer cells with IC50 values ranging from 11-21 nM. Additionally, the compound was 70 times more effective than p...